ReWalk Robotics (RWLK) Posts Wider-than-Expected Q3 Loss

ReWalk Robotics (NASDAQ: RWLK) reported Q3 EPS of ($1.34), versus the analyst estimate of ($0.28). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.58 million.

"We achieved several significant milestones during the third quarter of 2014 that allowed us to bring our revolutionary technology to a broader group of individuals with spinal cord injuries. Our market-leading position was strengthened this quarter when we received FDA clearance as the only powered exoskeleton that can be legally marketed in the U.S.," said Larry Jasinski, Chief Executive Officer. "We are excited to be able to provide wheelchair-bound individuals with access to the ReWalk system for daily use at home and in their communities, where they need it most."

"We also secured reimbursement on a case-by-case basis for ReWalk personal systems in the U.S. and Germany, paving the way for additional favorable coverage decisions by other major insurers. Importantly, we strengthened our balance sheet with the successful completion of our IPO. Building on the momentum generated during the third quarter, we will continue to aggressively execute our strategy in the U.S., Europe and other geographies," Jasinski concluded.

For earnings history and earnings-related data on ReWalk Robotics (RWLK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c